Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | $155.84M | $54.00M | $172.83M | $34.76M | $31.25M | $18.45M | $3.77M |
| Cost of Revenue | N/A | $118.66M | $106.78M | $87.57M | $67.08M | $40.09M | $33.97M |
| Gross Profit | $155.84M | $-64.67M | $66.05M | $-52.81M | $-35.83M | $-21.64M | $-30.20M |
| Gross Margin | 100.00% | -119.76% | 38.22% | -151.92% | -114.65% | -117.31% | -801.09% |
| Operating Expenses | $194.45M | $37.06M | $36.10M | $33.48M | $33.88M | $11.37M | $4.21M |
| Operating Income | $-38.62M | $-101.72M | $29.95M | $-86.29M | $-69.72M | $-33.01M | $-34.41M |
| Operating Margin | -24.78% | -188.39% | 17.33% | -248.24% | -223.07% | -178.94% | -912.71% |
| Net Income | $15.22M | $-96.99M | $37.51M | $-95.06M | $-229.35M | $-31.74M | $-31.44M |
| Net Margin | 9.77% | -179.63% | 21.71% | -273.45% | -733.84% | -172.05% | -834.06% |
| EPS (Basic) | $0.14 | $-1.20 | $0.55 | $-1.51 | $-4.78 | $-0.50 | $-0.50 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |